Current affairs 13 March 2025

India Poised to Become Largest Web3 Developer Hub by 2028.

• India is projected to lead globally in Web3 development by 2028, with 4.7 million developers joining GitHub in 2024, contributing 17% of new Web3 talent. Key focus areas include gaming, NFTs, DeFi, and RWAs, with 50% of developers entering the space within the last two years. India also ranks third globally in Web3 startup founders, with over 1,200 startups operating in the sector.

India’s Venture Capital Funding Surges 43% to $13.7 Billion in 2024.

• India’s venture capital funding grew 43% Year on Year to $13.7 billion in 2024, with 1,270 deals, making it Asia-Pacific’s second-largest VC market.
• Small and mid-sized deals grew 1.4x, while megadeals ($100M+) rose 1.6x, reviving pre-pandemic funding levels.
• Consumer tech led with $ 5.4 billion, driven by quick commerce, edtech, and B2C startups like Zepto, Meesho, and Lenskart.

52% Employees Face Burnout Due to Poor Work-Life Balance.

• A survey by Vertex Group across five Indian states found that 52% of employees experience burnout due to poor work-life balance.
• Post-pandemic challenges have intensified employee stress, highlighting the need for better work-life integration.
• The survey indicates a rising demand for flexible working hours and healthier professional-personal balance.

India’s Warehousing Demand Surges, Mumbai Leads Growth.

• India’s warehousing transactions rose 12% YoY to 56.4 mn sq ft in 2024, with 233 mn sq ft of unutilized land available for future demand.
• Mumbai led with 10.3 mn sq ft, while cities like Bengaluru, Kolkata, and Chennai saw 25-29% growth, driven by manufacturing and 3PL.
• Private equity investments surged 136% to USD 1,877 million, fueled by e-commerce and supply chain expansion.

Indian pharmaceutical exports ranked 11th globally.

• As per a secondary market research analysis published by Bain and Company in the year 2025, Indian pharmaceutical exports ranked 11th globally in value terms in the year 2023 and accounted for 3% of the total pharmaceutical exports.
• The Drugs and Cosmetics Act, 1940 amended in 2008 to provide for stringent penalties for manufacture of spurious and adulterated drugs.